SAFETY DATA SHEET

Gentamicin / Betamethasone Formulation

Version: 5.5
Revision Date: 23.03.2020
SDS Number: 434580-00015
Date of last issue: 13.09.2019
Date of first issue: 06.01.2016

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Gentamicin / Betamethasone Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 91-105 Harpin Street
           Bendigo 3550, Victoria Australia
Telephone: 908-740-4000
Emergency telephone number: 1 800 033 461
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 1 800 817 414

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Reproductive toxicity: Category 1A
Specific target organ toxicity - repeated exposure: Category 1 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland)

GHS label elements
Hazard pictograms: 
Signal word: Danger
Hazard statements: H360D May damage the unborn child.
                  H372 Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.
Precautionary statements: Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapours.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P281 Use personal protective equipment as required.
RESPONSE:
P308 + P313 IF exposed or concerned: Get medical advice/attention.

STORAGE:
P405 Store locked up.

DISPOSAL:
P501 Dispose of contents/container to an approved waste disposal plant.

OTHER HAZARDS WHICH DO NOT RESULT IN CLASSIFICATION
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance / Mixture: Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyethylene glycol stearate</td>
<td>9004-99-3</td>
<td>5</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>0.49</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>378-44-9</td>
<td>0.1</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES
General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES
Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
- None known.

Specific hazards during firefighting:
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

Hazchem Code:
- •3Z

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
- Use personal protective equipment.
- Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions:
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide drying or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
- If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling: Do not get on skin or clothing. Do not breathe vapours or spray mist. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyethylene glycol stearate</td>
<td>9004-99-3</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>AU OEL</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>TWA</td>
<td>0.1 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>betamethasone</td>
<td>378-44-9</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: Skin Wipe limit 10 µg/100 cm² Internal

Engineering measures: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted. Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

**Personal protective equipment**

- **Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - **Filter type**: Particulates type

- **Hand protection**: Chemical-resistant gloves

- **Eye protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

- **Skin and body protection**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

- **Appearance**: liquid
- **Colour**: No data available
- **Odour**: No data available
- **Odour Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: No data available
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: Not applicable
- **Flammability (liquids)**: No data available
### SAFETY DATA SHEET

**Gentamicin / Betamethasone Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.5</td>
<td>23.03.2020</td>
<td>434580-00015</td>
<td>13.09.2019</td>
<td>06.01.2016</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td></td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>No data available</td>
</tr>
<tr>
<td>Particle size</td>
<td>No data available</td>
</tr>
</tbody>
</table>

### SECTION 10. STABILITY AND REACTIVITY

- **Reactivity**: Not classified as a reactivity hazard.
- **Chemical stability**: Stable under normal conditions.
- **Possibility of hazardous reactions**: Can react with strong oxidizing agents.
- **Conditions to avoid**: None known.
- **Incompatible materials**: Oxidizing agents
- **Hazardous decomposition products**: No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

- **Exposure routes**: Inhalation, Skin contact, Ingestion, Eye contact

**Acute toxicity**
Not classified based on available information.
Product:
Acute inhalation toxicity : Acute toxicity estimate: > 5 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Method: Calculation method

Components:
Polyethylene glycol stearate:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Gentamicin:
Acute oral toxicity : LD50 (Rat): 8,000 - 10,000 mg/kg
  LD50 (Mouse): 10,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 0.2 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Remarks: No mortality observed at this dose.
Acute toxicity (other routes of administration) : LD50 (Rat): 67 - 96 mg/kg
  Application Route: Intravenous
  LD50 (Rat): 371 - 384 mg/kg
  Application Route: Intramuscular
  LDLo (Monkey): 30 mg/kg
  Application Route: Intravenous

betamethasone:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
  LD50 (Mouse): > 4,500 mg/kg
Acute inhalation toxicity : LC50 (Rat): 0.4 mg/l
  Exposure time: 4 h

Skin corrosion/irritation
Not classified based on available information.

Components:
Polyethylene glycol stearate:
Species : Rabbit
Result : No skin irritation

Gentamicin:
Species : Rabbit
Result : Mild skin irritation
betamethasone:
Species: Rabbit
Result: Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Polyethylene glycol stearate:
Species: Rabbit
Result: No eye irritation

Gentamicin:
Species: Rabbit
Result: Mild eye irritation

betamethasone:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Polyethylene glycol stearate:
Exposure routes: Skin contact
Species: Guinea pig
Result: negative

Gentamicin:
Remarks: No data available

betamethasone:
Exposure routes: Dermal
Species: Guinea pig
Result: Weak sensitizer

Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.

Components:

Polyethylene glycol stearate:
### Genotoxicity in vitro

**Gentamicin:**
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative

- Test Type: Chromosome aberration test in vitro
  - Result: equivocal

**Betamethasone:**
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative

- Test Type: Chromosome aberration test in vitro
  - Result: positive

**Genotoxicity in vivo**

**Gentamicin:**
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Intravenous injection
  - Result: negative

**Betamethasone:**
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Oral
  - Result: equivocal

### Germ cell mutagenicity - Assessment
- Weight of evidence does not support classification as a germ cell mutagen.

### Carcinogenicity
Not classified based on available information.

### Components:

#### Gentamicin:

- Carcinogenicity - Assessment: No data available

#### Reproductive toxicity
May damage the unborn child.

### Components:

#### Gentamicin:

- Effects on fertility: Two-generation reproduction toxicity study
  - Species: Rat
  - Fertility: NOAEL: 20 mg/kg body weight
  - Result: No significant adverse effects were reported
Effects on foetal development:

- **Gentamicin**:
  - Test Type: Embryo-foetal development
  - Species: Rabbit
  - Developmental Toxicity: NOAEL: 3.6 mg/kg body weight
  - Result: No embryo-foetal toxicity

- **Betamethasone**:
  - Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Intraperitoneal
  - Developmental Toxicity: LOAEL: 75 mg/kg body weight
  - Result: Embryo-foetal toxicity

  Test Type: Embryo-foetal development
  - Species: Mouse
  - Application Route: Intraperitoneal
  - Developmental Toxicity: LOAEL: 10 mg/kg body weight
  - Result: foetal mortality, No malformations were observed.

  Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Intraperitoneal
  - Developmental Toxicity: LOAEL: 50 mg/kg body weight
  - Result: foetal mortality, No malformations were observed.

Reproductive toxicity - Assessment:

- Positive evidence of adverse effects on development from human epidemiological studies.

**betamethasone**:

Effects on foetal development:

- Species: Rabbit
  - Application Route: Intramuscular
  - Developmental Toxicity: LOAEL: 0.05 mg/kg body weight
  - Result: Fetotoxicity, Malformations were observed.

- Species: Rat
  - Application Route: Subcutaneous
  - Developmental Toxicity: LOAEL: 0.42 mg/kg body weight
  - Result: Malformations were observed.

- Species: Mouse
  - Application Route: Intramuscular
  - Developmental Toxicity: LOAEL: 1 mg/kg body weight
  - Result: Malformations were observed.

Reproductive toxicity - Assessment:

- Clear evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.
Components:

Gentamicin:
Target Organs: Kidney, inner ear
Assessment: Causes damage to organs through prolonged or repeated exposure.

betamethasone:
Target Organs: Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Gentamicin:
Species: Dog
LOAEL: 3 mg/kg
Application Route: Intramuscular
Exposure time: 12 Months
Target Organs: Kidney
Symptoms: Vomiting, Salivation

Species: Monkey
LOAEL: 50 mg/kg
Application Route: Subcutaneous
Exposure time: 3 Weeks
Target Organs: Kidney, inner ear

Species: Monkey
LOAEL: 6 mg/kg
Application Route: Intramuscular
Exposure time: 3 Weeks
Target Organs: Blood, Kidney, inner ear, Liver

Species: Rat
NOAEL: 5 mg/kg
LOAEL: 10 mg/kg
Application Route: Intramuscular
Exposure time: 52 Weeks
Target Organs: Kidney, Blood

Species: Rat
NOAEL: 12.5 mg/kg
LOAEL: 50 mg/kg
Application Route: Intramuscular
Exposure time: 13 Weeks
Target Organs: Kidney

betamethasone:
Species: Rabbit
### SAFeTy DATA SHEET

**Gentamicin / Betamethasone Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.5</td>
<td>23.03.2020</td>
<td>434580-00015</td>
<td>13.09.2019</td>
<td>06.01.2016</td>
</tr>
</tbody>
</table>

- **LOAEL**: 0.05 %
- **Application Route**: Skin contact
- **Exposure time**: 10 - 30 d
- **Target Organs**: Pituitary gland, Immune system, muscle

#### Species: Rat
- **LOAEL**: 0.05 %
- **Application Route**: Skin contact
- **Exposure time**: 8 Weeks
- **Target Organs**: thymus gland

#### Species: Mouse
- **LOAEL**: 0.1 %
- **Application Route**: Skin contact
- **Exposure time**: 8 Weeks
- **Target Organs**: thymus gland

#### Species: Dog
- **LOAEL**: 0.05 mg/kg
- **Application Route**: Oral
- **Exposure time**: 28 d
- **Target Organs**: Blood, thymus gland, Adrenal gland

**Aspiration toxicity**
Not classified based on available information.

**Experience with human exposure**

#### Components:

**Gentamicin:**
- **Ingestion**: Target Organs: Kidney, inner ear
- Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness

**betamethasone:**
- **Inhalation**: Target Organs: Adrenal gland
- **Skin contact**: Symptoms: Redness, pruritis, Irritation

### SECTION 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

**Components:**

**Polyethylene glycol stearate:**
- **Toxicity to fish**: LC50 (Leuciscus idus (Golden orfe)): > 10,000 mg/l
  
- **Exposure time**: 96 h
  **Method**: DIN 38412

- **Toxicity to microorganisms**: EC10: > 10,000 mg/l
  **Exposure time**: 16 h

**Gentamicin:**
### Toxicity to daphnia and other aquatic invertebrates
- **EC50** (Daphnia magna (Water flea)): 86 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202

- **LC50** (Americamysis): 30 mg/l
  - Exposure time: 96 h

### Toxicity to algae/aquatic plants
- **EC50** (Pseudokirchneriella subcapitata (green algae)): 10 µg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

- **NOEC** (Pseudokirchneriella subcapitata (green algae)): 1.5 µg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

- **EC50** (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

- **NOEC** (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

### Toxicity to microorganisms
- **EC50**: 288.7 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209

### betamethasone:

#### Toxicity to daphnia and other aquatic invertebrates
- **EC50** (Americamysis): > 50 mg/l
  - Exposure time: 96 h

#### Toxicity to algae/aquatic plants
- **EC50** (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
  - Remarks: No toxicity at the limit of solubility

- **NOEC** (Pseudokirchneriella subcapitata (green algae)): 34 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
  - Remarks: No toxicity at the limit of solubility

#### Toxicity to fish (Chronic toxicity)
- **NOEC** (Pimephales promelas (fathead minnow)): 0.052 mg/l
  - Exposure time: 32 d
  - Method: OECD Test Guideline 210

- **NOEC** (Oryzias latipes (Japanese medaka)): 0.07 µg/l
  - Exposure time: 219 d
  - Method: OECD Test Guideline 229
SAFETY DATA SHEET

Gentamicin / Betamethasone Formulation

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 8 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Persistence and degradability

Components:

Polyethylene glycol stearate:
Biodegradability: Result: Readily biodegradable
Biodegradation: > 70 %
Exposure time: 10 d
Method: OECD Test Guideline 302B

Gentamicin:
Biodegradability: Result: rapidly degradable
Biodegradation: 100 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Polyethylene glycol stearate:
Partition coefficient: n-octanol/water: log Pow: 6.16

Gentamicin:
Partition coefficient: n-octanol/water: log Pow: < -2

Betamethasone:
Partition coefficient: n-octanol/water: log Pow: 2.11

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
### SAFETY DATA SHEET

**Gentamicin / Betamethasone Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.5</td>
<td>23.03.2020</td>
<td>434580-00015</td>
<td>13.09.2019</td>
<td>06.01.2016</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>UNRTDG</strong></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>UN number</td>
<td>: UN 3082</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proper shipping name</td>
<td>: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Gentamicin, Benzalkonium chloride)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class</td>
<td>: 9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Packing group</td>
<td>: III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labels</td>
<td>: 9</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **IATA-DGR** |  |  |  |  |
| UN/ID No.    | : UN 3082      |  |  |  |
| Proper shipping name | : Environmentally hazardous substance, liquid, n.o.s. (Gentamicin, Benzalkonium chloride) |  |  |  |
| Class        | : 9            |  |  |  |
| Packing group | : III         |  |  |  |
| Labels       | : Miscellaneous|  |  |  |
| Packing instruction (cargo aircraft) | : 964 |  |  |  |
| Packing instruction (passenger aircraft) | : 964 |  |  |  |
| Environmentally hazardous | : yes |  |  |  |

| **IMDG-Code** |  |  |  |  |
| UN number     | : UN 3082      |  |  |  |
| Proper shipping name | : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Gentamicin, Benzalkonium chloride) |  |  |  |
| Class         | : 9            |  |  |  |
| Packing group | : III         |  |  |  |
| Labels        | : 9            |  |  |  |
| EmS Code      | : F-A, S-F    |  |  |  |
| Marine pollutant | : yes   |  |  |  |

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

### National Regulations

| **ADG** |  |  |  |  |
| UN number | : UN 3082      |  |  |  |
| Proper shipping name | : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Gentamicin, Benzalkonium chloride) |  |  |  |
| Class      | : 9            |  |  |  |
| Packing group | : III         |  |  |  |
| Labels     | : 9            |  |  |  |
| Hazchem Code | : •3Z    |  |  |  |

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.
SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Prohibition/Licensing Requirements: There is no applicable prohibition or notification/licensing requirements, including for carcinogens under Commonwealth, State or Territory legislation.

The components of this product are reported in the following inventories:

- **AICS**: not determined
- **DSL**: not determined
- **IECSC**: not determined

SECTION 16. OTHER INFORMATION

Further information

- **Revision Date**: 23.03.2020
- **Date format**: dd.mm.yyyy

Full text of other abbreviations

- **ACGIH**: USA. ACGIH Threshold Limit Values (TLV)
- **AU OEL**: Australia. Workplace Exposure Standards for Airborne Contaminants.
- **ACGIH / TWA**: 8-hour, time-weighted average
- **AU OEL / TWA**: Exposure standard - time weighted average

Abbreviations:

- **AICS**: Australian Inventory of Chemical Substances
- **ANTT**: National Agency for Transport by Land of Brazil
- **ASTM**: American Society for the Testing of Materials
- **bw**: Body weight
- **CMR**: Carcinogen, Mutagen or Reproductive Toxicant
- **DIN**: Standard of the German Institute for Standardisation
- **DSL**: Domestic Substances List (Canada)
- **ECx**: Concentration associated with x% growth rate response
- **ErCx**: Concentration associated with x% response
- **EmS**: Emergency Schedule
- **ENCS**: Existing and New Chemical Substances (Japan)
- **ELx**: Loading rate associated with x% response
- **ErCx**: Concentration associated with x% response
- **ERG**: Emergency Response Guide
- **GHS**: Globally Harmonized System
- **GLP**: Good Laboratory Practice
- **IARC**: International Agency for Research on Cancer
- **IATA**: International Air Transport Association
- **IBC**: International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk
- **IC50**: Half maximal inhibitory concentration
- **ICAO**: International Civil Aviation Organization
- **IECSC**: Inventory of Existing Chemical Substances in China
- **IMDG**: International Maritime Dangerous Goods
- **IMO**: International Maritime Organization
- **ISHL**: Industrial Safety and Health Law (Japan)
- **ISO**: International Organisation for Standardization
- **KECI**: Korea Existing Chemicals Inventory
- **LD50**: Lethal Dose to 50% of a test population
- **LC50**: Lethal Concentration to 50% of a test population
- **Median**
SAFETY DATA SHEET

Gentamicin / Betamethasone Formulation

Version 5.5
Revision Date: 23.03.2020
SDS Number: 434580-00015
Date of last issue: 13.09.2019
Date of first issue: 06.01.2016

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

AU / EN